BACKGROUND: Patients and payers wish to identify hospitals with good surgical oncology outcomes. Our objective was to determine whether differences in outcomes explained by hospital structural characteristics are mitigated by differences in patient severity. METHODS: Using hospital administrative and cancer registry records in Pennsylvania, we identified 24,618 adults hospitalized for cancer-related operations. Colorectal, prostate, endometrial, ovarian, head and neck, lung, esophageal, and pancreatic cancers were studied. Outcome measures were 30-day mortality and failure to rescue (FTR) (30-day mortality preceded by a complication). After severity of illness adjustment, we estimated logistic regression models to predict the likelihood of both outcomes. In addition to American Hospital Association survey data, we externally verified hospitals with National Cancer Institute (NCI) cancer center or Commission on Cancer (COC) cancer program status. RESULTS: Patients in hospitals with NCI cancer centers were significantly younger and less acutely ill on admission (P < .001). Patients in high volume hospitals were younger, had lower admission acuity, yet had more advanced cancer (P < .001). Unadjusted 30-day mortality rates were lower in NCI-designated hospitals (3.76% vs 2.17%;P = .01). Risk-adjusted FTR rates were significantly lower in NCI-designated hospitals (4.86% vs 3.51%;P = .03). NCI center designation was a significant predictor of 30-day mortality when considering patient and hospital characteristics (OR, 0.68; 95% CI, 0.47-0.97;P = .04). We did not find significant outcomes effects based on COC cancer program approval. CONCLUSION: Patient severity of illness varies significantly across hospitals, which may explain the outcome differences observed. Severity adjustment is crucial to understanding outcome differences. Outcomes were better than predicted for NCI-designated hospitals. Copyright 2010 Mosby, Inc. All rights reserved.
BACKGROUND:Patients and payers wish to identify hospitals with good surgical oncology outcomes. Our objective was to determine whether differences in outcomes explained by hospital structural characteristics are mitigated by differences in patient severity. METHODS: Using hospital administrative and cancer registry records in Pennsylvania, we identified 24,618 adults hospitalized for cancer-related operations. Colorectal, prostate, endometrial, ovarian, head and neck, lung, esophageal, and pancreatic cancers were studied. Outcome measures were 30-day mortality and failure to rescue (FTR) (30-day mortality preceded by a complication). After severity of illness adjustment, we estimated logistic regression models to predict the likelihood of both outcomes. In addition to American Hospital Association survey data, we externally verified hospitals with National Cancer Institute (NCI) cancer center or Commission on Cancer (COC) cancer program status. RESULTS:Patients in hospitals with NCI cancer centers were significantly younger and less acutely ill on admission (P < .001). Patients in high volume hospitals were younger, had lower admission acuity, yet had more advanced cancer (P < .001). Unadjusted 30-day mortality rates were lower in NCI-designated hospitals (3.76% vs 2.17%;P = .01). Risk-adjusted FTR rates were significantly lower in NCI-designated hospitals (4.86% vs 3.51%;P = .03). NCI center designation was a significant predictor of 30-day mortality when considering patient and hospital characteristics (OR, 0.68; 95% CI, 0.47-0.97;P = .04). We did not find significant outcomes effects based on COC cancer program approval. CONCLUSION:Patient severity of illness varies significantly across hospitals, which may explain the outcome differences observed. Severity adjustment is crucial to understanding outcome differences. Outcomes were better than predicted for NCI-designated hospitals. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: A J Hartz; H Krakauer; E M Kuhn; M Young; S J Jacobsen; G Gay; L Muenz; M Katzoff; R C Bailey; A A Rimm Journal: N Engl J Med Date: 1989-12-21 Impact factor: 91.245
Authors: Jeffrey A Meyerhardt; Paul J Catalano; Deborah Schrag; John Z Ayanian; Daniel G Haller; Robert J Mayer; John S Macdonald; Al B Benson; Charles S Fuchs Journal: Ann Intern Med Date: 2003-10-21 Impact factor: 25.391
Authors: Deborah Schrag; Katherine S Panageas; Elyn Riedel; Lillian Hsieh; Peter B Bach; Jose G Guillem; Colin B Begg Journal: J Surg Oncol Date: 2003-06 Impact factor: 3.454
Authors: David C Hodgson; Wei Zhang; Alan M Zaslavsky; Charles S Fuchs; William E Wright; John Z Ayanian Journal: J Natl Cancer Inst Date: 2003-05-21 Impact factor: 13.506
Authors: Elizabeth B Lamont; Davinder Hayreh; Kate E Pickett; James J Dignam; Marcy A List; Kerstin M Stenson; Daniel J Haraf; Bruce E Brockstein; Sarah A Sellergren; Everett E Vokes Journal: J Natl Cancer Inst Date: 2003-09-17 Impact factor: 13.506
Authors: Mila H Ju; Jeanette W Chung; Christine V Kinnier; David J Bentrem; David M Mahvi; Clifford Y Ko; Karl Y Bilimoria Journal: Ann Surg Date: 2014-09 Impact factor: 12.969
Authors: Haejin In; Bridget A Neville; Stuart R Lipsitz; Katherine A Corso; Jane C Weeks; Caprice C Greenberg Journal: Ann Surg Date: 2012-05 Impact factor: 12.969
Authors: Danielle K DePeralta; Takuya Ogami; Jun-Min Zhou; Michael J Schell; Benjamin D Powers; Pamela J Hodul; Mokenge P Malafa; Jason B Fleming Journal: HPB (Oxford) Date: 2019-09-25 Impact factor: 3.647
Authors: M Schootman; M Lian; S L Pruitt; S Hendren; M Mutch; A D Deshpande; D B Jeffe; N O Davidson Journal: Ann Surg Oncol Date: 2014-04-21 Impact factor: 5.344
Authors: Daniel E Abbott; Scott B Cantor; Chung-Yuan Hu; Thomas A Aloia; Y Nancy You; Sa Nguyen; George J Chang Journal: J Am Coll Surg Date: 2012-05-04 Impact factor: 6.113
Authors: Li Tao; Richard B Schwab; Yazmin San Miguel; Scarlett Lin Gomez; Alison J Canchola; Manuela Gago-Dominguez; Ian K Komenaka; James D Murphy; Alfredo A Molinolo; Maria Elena Martinez Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-17 Impact factor: 4.254